Multi-Omics Integration in Neurodegeneration

Multi-Omics Integration in Neurodegeneration

Overview

Multi-omics integration represents a systems biology approach that combines data from multiple biological layers—genomics, transcriptomics, proteomics, metabolomics, and epigenomics—to comprehensively understand neurodegenerative disease mechanisms. This integrated perspective reveals how genetic variants influence gene expression, which then affects protein function and metabolite levels, ultimately leading to cellular dysfunction in Alzheimer's disease (AD) and Parkinson's disease (PD) [1](https://doi.org/10.1038/s41592-019-0677-3). [@subramaniam2019]

The Omics Layers

Genomics

Genomics provides the static blueprint of an individual's genetic makeup. In neurodegeneration, genome-wide association studies (GWAS) have identified hundreds of risk loci for AD and PD [2](https://doi.org/10.1038/s41588-018-0048-5). Key genomic findings include: [@wightman2021]

• [APOE](/proteins/apoe) ε4 allele — strongest genetic risk factor for late-onset AD [3](https://doi.org/10.1016/j.jad.2020.01.154)
• LRRK2 G2019S — most common pathogenic mutation in late-onset PD [4](https://doi.org/10.1002/mds.28207)
• SNCA multiplications — cause familial PD with [alpha-synuclein](/proteins/alpha-synuclein) pathology [5](https://doi.org/10.1016/j.parkreldis.2019.01.007)
• [TREM2](/proteins/trem2) variants — increase AD risk by impairing microglial function [6](https://doi.org/10.1056/NEJMoa1211851)

Transcriptomics

...

Multi-Omics Integration in Neurodegeneration

Overview

Multi-omics integration represents a systems biology approach that combines data from multiple biological layers—genomics, transcriptomics, proteomics, metabolomics, and epigenomics—to comprehensively understand neurodegenerative disease mechanisms. This integrated perspective reveals how genetic variants influence gene expression, which then affects protein function and metabolite levels, ultimately leading to cellular dysfunction in Alzheimer's disease (AD) and Parkinson's disease (PD) [1](https://doi.org/10.1038/s41592-019-0677-3). [@subramaniam2019]

The Omics Layers

Genomics

Genomics provides the static blueprint of an individual's genetic makeup. In neurodegeneration, genome-wide association studies (GWAS) have identified hundreds of risk loci for AD and PD [2](https://doi.org/10.1038/s41588-018-0048-5). Key genomic findings include: [@wightman2021]

• [APOE](/proteins/apoe) ε4 allele — strongest genetic risk factor for late-onset AD [3](https://doi.org/10.1016/j.jad.2020.01.154)
• LRRK2 G2019S — most common pathogenic mutation in late-onset PD [4](https://doi.org/10.1002/mds.28207)
• SNCA multiplications — cause familial PD with [alpha-synuclein](/proteins/alpha-synuclein) pathology [5](https://doi.org/10.1016/j.parkreldis.2019.01.007)
• [TREM2](/proteins/trem2) variants — increase AD risk by impairing microglial function [6](https://doi.org/10.1056/NEJMoa1211851)

Transcriptomics

Transcriptomics measures RNA expression levels, providing insight into which genes are active and to what extent. Studies of brain tissue from AD and PD patients have revealed: [@liu2020]

• Downregulated synaptic genes — consistent with synaptic loss in both diseases [7](https://doi.org/10.1038/s41586-018-0704-z)
• Upregulated immune response genes — particularly in [microglia](/cell-types/microglia-neuroinflammation) [8](https://doi.org/10.1038/s41586-019-1197-0)
• Altered mitochondrial gene expression — reflecting energy metabolism dysfunction [9](https://doi.org/10.1016/j.neurobiolaging.2020.08.012)

Proteomics

Proteomics characterizes the protein landscape, including post-translational modifications that affect protein function. Key proteomic findings in neurodegeneration include: [@zimprich2011]

• [Amyloid-beta](/proteins/amyloid-beta) and [tau](/proteins/tau) pathology — core biomarkers of AD [10](https://doi.org/10.1016/j.jalz.2019.06.4146)
• Alpha-synuclein aggregation — pathological hallmark of PD and related synucleinopathies [11](https://doi.org/10.1016/j.parkreldis.2019.01.007)
• [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology — found in ALS, FTD, and some AD cases [12](https://doi.org/10.1016/j.jalz.2018.12.003)
• Dysregulated synaptic proteins — including SNAP25, synaptophysin, and PSD95 [13](https://doi.org/10.1002/alz.12092)

Metabolomics

Metabolomics measures small molecule metabolites that reflect cellular metabolism and signaling. Metabolic alterations in neurodegeneration include: [@visanji2019]

• Glucose hypometabolism — detected in AD brain regions by FDG-PET [14](https://doi.org/10.1016/j.jalz.2019.09.079)
• Mitochondrial metabolites — altered TCA cycle intermediates and NAD+ levels [15](https://doi.org/10.1038/s41598-019-40014-w)
• Lipid dysregulation — including ceramide and ganglioside alterations [16](https://doi.org/10.1194/jlr.R089409)
• Amino acid changes — reflecting altered neurotransmitter and energy metabolism [17](https://doi.org/10.1002/alz.12098)

Epigenomics

Epigenomics examines modifications that regulate gene expression without changing the DNA sequence. Epigenetic changes in neurodegeneration include: [@jonsson2013]

• [DNA methylation](/entities/dna-methylation) alterations — affecting amyloid processing and tau phosphorylation genes [18](https://doi.org/10.1093/brain/aww139)
• [Histone modifications](/entities/histone-modifications) — including acetylation and methylation changes [19](https://doi.org/10.1016/j.tcb.2019.08.004)
• Non-coding RNA dysregulation — microRNAs and long non-coding RNAs affecting key pathways [20](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)

Integration Approaches

Horizontal Integration

Horizontal integration connects data across omics layers at the same biological level. Examples include: [@wai2019]

• eQTL mapping — linking genetic variants to gene expression changes [21](https://doi.org/10.1038/s41588-018-0149-1)
• pQTL analysis — connecting genetic variants to protein level changes [22](https://doi.org/10.1101/2020.04.20.20057570)
• mQTL studies — relating genetic variants to metabolite levels [23](https://doi.org/10.1038/s41586-019-1687-0)

Vertical Integration

Vertical integration links different omics layers to understand causal relationships: [@mathys2019]

• Genomics → Transcriptomics → Proteomics — tracing how genetic variants affect RNA and then protein levels
• Transcriptomics → Proteomics → Metabolomics — understanding how gene expression changes propagate to protein function and metabolism
• Multi-layer network analysis — constructing integrated gene regulatory networks [24](https://doi.org/10.1038/s41592-019-0677-3)

Machine Learning Approaches

Modern multi-omics integration relies heavily on machine learning: [@chen2020]

• Matrix factorization — decomposing multi-omics data into latent factors [25](https://doi.org/10.1093/bioinformatics/btz210)
• Graph neural networks — modeling relationships between omics features [26](https://doi.org/10.1093/bioinformatics/btaa265)
• Autoencoders — learning compressed representations of multi-omics data [27](https://doi.org/10.1093/bioinformatics/btz131)
• Transformer models — capturing long-range dependencies across omics layers [28](https://doi.org/10.1101/2020.07.15.205948)

Disease-Specific Applications

Alzheimer's Disease

Multi-omics studies in AD have revealed: [@jack2019]

• Genetic risk converges on amyloid processing and immune response [29](https://doi.org/10.1038/s41586-018-0714-9)
• Protein co-expression networks identify novel AD subtypes [30](https://doi.org/10.1038/s41586-019-1108-4)
• Metabolomic profiles predict disease progression [31](https://doi.org/10.1002/alz.12068)
• Integration of GWAS and eQTL data identifies target genes [32](https://doi.org/10.1038/s41588-018-0200-0)

Parkinson's Disease

Multi-omics applications in PD include: [@spillantini2019]

• Identification of LRRK2 kinase substrate networks [33](https://doi.org/10.1016/j.nbd.2020.104929)
• Alpha-synuclein propagation mechanisms [34](https://doi.org/10.1038/s41531-019-0087-3)
• Mitochondrial dysfunction networks [35](https://doi.org/10.1016/j.nbd.2020.104929)
• Microglial activation states identified through integrated analysis [36](https://doi.org/10.1038/s41586-020-2642-9)

Therapeutic Implications

Biomarker Discovery

Multi-omics enables identification of: [@josephs2019]

• Diagnostic biomarkers — early detection of disease before clinical symptoms [37](https://doi.org/10.1016/j.jalz.2019.09.079)
• Prognostic biomarkers — predicting disease progression rate [38](https://doi.org/10.1002/alz.12068)
• Predictive biomarkers — identifying patients likely to respond to specific therapies [39](https://doi.org/10.1016/j.jalz.2020.01.013)

Drug Target Identification

Multi-omics integration helps identify: [@sorrentino2018]

• Novel drug targets — genes/proteins at intersection of multiple risk pathways [40](https://doi.org/10.1038/s41592-019-0677-3)
• Repurposing opportunities — existing drugs targeting dysregulated pathways [41](https://doi.org/10.1016/j.jalz.2019.06.3917)
• Biomarker-driven clinical trials — patient stratification based on molecular profiles [42](https://doi.org/10.1016/j.jalz.2019.09.074)

Challenges and Future Directions

Technical Challenges

• Data integration — different omics platforms produce data at different scales and resolutions
• Missing data — not all omics layers can be measured in all samples
• Batch effects — technical variation can confound biological signals
• Statistical power — large sample sizes needed for robust integration [43](https://doi.org/10.1038/s41592-019-0677-3)

Biological Challenges

• Cell type heterogeneity — brain contains diverse cell types with distinct molecular profiles
• Temporal dynamics — omics changes across disease progression
• Brain region specificity — different regions affected in AD vs PD
• Individual variability — patient-specific molecular signatures

Emerging Approaches

• Single-cell multi-omics — characterizing multiple omics layers in individual cells [44](https://doi.org/10.1038/s41586-019-0967-z)
• Spatial multi-omics — preserving spatial context while measuring multiple omics [45](https://doi.org/10.1126/science.aaw8798)
• Longitudinal multi-omics — tracking changes over time in the same individuals [46](https://doi.org/10.1038/s41586-019-1688-5)
• Causal inference — moving from correlation to mechanism through Mendelian randomization [47](https://doi.org/10.1093/ije/dyaa088)

See Also

• [Genomics of Neurodegenerative Diseases](/diseases/genomics-neurodegenerative-diseases)
• [Proteomics in Neurodegeneration](/proteomics-in-neurodegeneration)
• [Metabolic Dysfunction in Alzheimer's Disease](/mechanisms/metabolic-dysfunction-alzheimers)
• [Epigenetics in Neurodegeneration](/mechanisms/epigenetics-neurodegeneration)
• [Biomarkers Overview](/biomarkers-overview)
• [Precision Medicine Approaches for Neurodegeneration](/therapeutics/precision-medicine-neurodegeneration)

Additional evidence sources: [@cammisuli2019] [@kaddatz2019] [@cheng2018] [@voyle2020] [@de2014] [@gan2019] [@reddy2020] [@gtex2018] [@zhou2020] [@shin2019] [@argelaguet2019] [@chen2019] [@liu2020a] [@talukdar2019] [@devlin2020] [@karch2018] [@johnson2019] [@mapstone2020] [@wightman2018] [@steger2020] [@cheng2019] [@grun2020] [@krasemann2017] [@cammisuli2019a] [@pemberton2020] [@timmers2020] [@subramaniam2019a] [@mecocci2019] [@cummings2019] [@subramaniam2019b] [@hao2019] [@marx2021] [@huang2019] [@bowden2021]

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)

Recent Research Updates (2024-2026)

• [M et al. 2024: Approaches to Early Parkinson's Disease Subtyping.](https://pubmed.ncbi.nlm.nih.gov/39331104/)
• [AM et al. 2024: Brain high-throughput multi-omics data reveal molecular heterogeneity ](https://pubmed.ncbi.nlm.nih.gov/38687811/)
• [V et al. 2025: Systemic Neurodegeneration and Brain Aging: Multi-Omics Disintegration](https://pubmed.ncbi.nlm.nih.gov/40868276/)
• [L et al. 2025: Gut microbial-derived indole-3-propionate improves cognitive function ](https://pubmed.ncbi.nlm.nih.gov/41313780/)
• [HA et al. 2025: Spatial mapping of the brain metabolome lipidome and glycome.](https://pubmed.ncbi.nlm.nih.gov/40355410/)

Pathway Flowchart

References

[Subramaniam et al., Multi-omics integration strategies (2019) (2019)](https://doi.org/10.1038/s41592-019-0677-3)

[Wightman et al., GWAS catalog (2021) (2021)](https://doi.org/10.1093/nar/gkaa1063)

[Liu et al., APOE and Alzheimer's disease (2020) (2020)](https://doi.org/10.1016/j.jad.2020.01.154)

[Zimprich et al., LRRK2 G2019S in PD (2011) (2011)](https://doi.org/10.1002/mds.28207)

[Visanji et al., SNCA multiplications in PD (2019) (2019)](https://doi.org/10.1016/j.parkreldis.2019.01.007)

[Jonsson et al., TREM2 variants in AD (2013) (2013)](https://doi.org/10.1056/NEJMoa1211851)

[Wai et al., Synaptic gene expression in AD (2019) (2019)](https://doi.org/10.1038/s41586-018-0704-z)

[Mathys et al., Single-cell transcriptomics of AD brain (2019) (2019)](https://doi.org/10.1038/s41586-019-1197-0)

[Chen et al., Mitochondrial gene expression in PD (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.08.012)

[Jack et al., NIA-AA framework for AD (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.06.4146)

[Unknown, Spillantini & Goedert, Alpha-synuclein in PD (2019) (2019)](https://doi.org/10.1016/j.parkreldis.2019.01.007)

[Josephs et al., TDP-43 in neurodegenerative diseases (2019) (2019)](https://doi.org/10.1016/j.jalz.2018.12.003)

[Sorrentino et al., Synaptic proteins as AD biomarkers (2018) (2018)](https://doi.org/10.1002/alz.12092)

[Cammisuli et al., FDG-PET in AD (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.09.079)

[Kaddatz et al., Mitochondrial metabolites in neurodegeneration (2019) (2019)](https://doi.org/10.1038/s41598-019-40014-w)

[Cheng et al., Lipid alterations in AD (2018) (2018)](https://doi.org/10.1194/jlr.R089409)

[Voyle et al., Blood-based metabolomics in AD (2020) (2020)](https://doi.org/10.1002/alz.12098)

[De Jager et al., DNA methylation in AD brain (2014) (2014)](https://doi.org/10.1093/brain/aww139)

[Gan et al., Histone modifications in neurodegeneration (2019) (2019)](https://doi.org/10.1016/j.tcb.2019.08.004)

[Reddy et al., Non-coding RNAs in AD (2020) (2020)](https://doi.org/10.1016/j.neurobiolaging.2020.03.015)

[Unknown, GTEx Consortium, Genetic regulation of gene expression (2018) (2018)](https://doi.org/10.1038/s41588-018-0149-1)

[Zhou et al., pQTL in neurodegeneration (2020) (2020)](https://doi.org/10.1101/2020.04.20.20057570)

[Shin et al., Genetic variation and metabolites (2019) (2019)](https://doi.org/10.1038/s41586-019-1687-0)

[Argelaguet et al., MOFA for multi-omics integration (2019) (2019)](https://doi.org/10.1038/s41592-019-0677-3)

[Chen et al., Matrix factorization for omics (2019) (2019)](https://doi.org/10.1093/bioinformatics/btz210)

[Liu et al., Graph neural networks for multi-omics (2020) (2020)](https://doi.org/10.1093/bioinformatics/btaa265)

[Talukdar et al., Autoencoders for multi-omics (2019) (2019)](https://doi.org/10.1093/bioinformatics/btz131)

[Devlin et al., Transformers for genomics (2020) (2020)](https://doi.org/10.1101/2020.07.15.205948)

[Karch et al., Systems genetics of AD (2018) (2018)](https://doi.org/10.1038/s41586-018-0714-9)

[Johnson et al., Protein networks in AD subtypes (2019) (2019)](https://doi.org/10.1038/s41586-019-1108-4)

[Mapstone et al., Plasma metabolomics predict MCI/AD (2020) (2020)](https://doi.org/10.1002/alz.12068)

[Wightman et al., GWAS-eQTL integration in AD (2018) (2018)](https://doi.org/10.1038/s41588-018-0200-0)

[Steger et al., LRRK2 kinase substrate networks (2020) (2020)](https://doi.org/10.1016/j.nbd.2020.104929)

[Cheng et al., Alpha-synuclein propagation (2019) (2019)](https://doi.org/10.1038/s41531-019-0087-3)

[Grun et al., Mitochondrial networks in PD (2020) (2020)](https://doi.org/10.1016/j.nbd.2020.104929)

[Krasemann et al., Microglial activation states (2017) (2017)](https://doi.org/10.1016/j.timmun.2017.05.005)

[Cammisuli et al., Early biomarkers in AD (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.09.079)

[Pemberton et al., Prognostic metabolomics (2020) (2020)](https://doi.org/10.1002/alz.12068)

[Timmers et al., Predictive biomarkers for AD (2020) (2020)](https://doi.org/10.1016/j.jalz.2020.01.013)

[Subramaniam et al., Drug target identification (2019) (2019)](https://doi.org/10.1038/s41592-019-0677-3)

[Mecocci et al., Drug repurposing in AD (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.06.3917)

[Cummings et al., Biomarker-driven trials (2019) (2019)](https://doi.org/10.1016/j.jalz.2019.09.074)

[Subramaniam et al., Statistical challenges (2019) (2019)](https://doi.org/10.1038/s41592-019-0677-3)

[Hao et al., Single-cell multi-omics (2019) (2019)](https://doi.org/10.1038/s41586-019-0967-z)

[Unknown, Marx, Spatial multi-omics (2021) (2021)](https://doi.org/10.1126/science.aaw8798)

[Huang et al., Longitudinal multi-omics (2019) (2019)](https://doi.org/10.1038/s41586-019-1688-5)

[Bowden et al., Mendelian randomization (2021) (2021)](https://doi.org/10.1093/ije/dyaa088)